Hoe verhoudt FP10's PB Ratio zich tot zijn concurrenten?

FP10 is een goede waarde op basis van zijn Price-To-Book Ratio (0.9x) vergeleken met het gemiddelde van gelijken (15.2x).

Hoe verhoudt FP10's PB Ratio zich tot andere bedrijven in de DE Biotechs industrie?

FP10 is een goede waarde op basis van de Price-To-Book -ratio ( 0.9 x) vergeleken met het German Biotechs -industriegemiddelde ( 2 x).

Wat is FP10's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { FP10 te berekenen voor waarderinganalyse.

Wat is de reële prijs van FP10 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van FP10 te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Salarius Pharmaceuticals (DB:FP10) - Aandelenkoers, Nieuws & Analyse

FP10 Overzicht aandelen

A clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Meer informatie

FP10 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €2M )

Heeft minder dan 1 jaar cash runway

+ 3 meer risico's

Salarius Pharmaceuticals, Inc. Concurrenten

bioXXmed

XTRA:T5O

€1.4m

4SC

DB:VSC

€48.2m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Salarius Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$3.01
52 Week Hoogtepunt	US$6.40
52 Week Laag	US$2.74
Bèta	0.96
11 maand verandering	0%
3 maanden verandering	0%
1 Jaar Verandering	-48.49%
33 jaar verandering	-98.23%
5 jaar verandering	-99.75%
Verandering sinds IPO	-99.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	FP10	DE Biotechs	DE Markt
7D	0%	-0.7%	-0.02%
1Y	-48.5%	-17.2%	8.2%

Rendement versus industrie: FP10 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -17.2 % opleverde.

Rendement versus markt: FP10 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.2 % opleverde.

Prijsvolatiliteit

Is FP10's price volatile compared to industry and market?
FP10 volatility
FP10 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stabiele aandelenkoers: FP10 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van FP10 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	2	David Arthur	www.salariuspharma.com

Salarius Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Salarius Pharmaceuticals zich tot de beurswaarde?
FP10 fundamentele statistieken
Marktkapitalisatie	€1.97m
Inkomsten(TTM)	-€5.86m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is FP10 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
FP10 resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$6.46m
Inkomsten	-US$6.46m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-4.49
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde FP10 op de lange termijn?

Bekijk historische prestaties en vergelijking

FP10 Overzicht aandelen

Risicoanalyse

Salarius Pharmaceuticals, Inc. Concurrenten

XTRA:T5O

€1.4m

DB:VSC

€48.2m

XTRA:CNW

€6.5m

XTRA:MDG1

€22.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Recent updates

Salarius Pharmaceuticals, Inc., Annual General Meeting, Dec 20, 2024

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting

New major risk - Shareholder dilution

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

New 90-day high: €1.16

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

New 90-day high: €1.05

New 90-day high: €0.88

Third quarter 2020 earnings released: US$0.096 loss per share

Revenue beats expectations

New 90-day low: €0.66

New 90-day low: €0.67

New 90-day low - €0.79

New 90-day low - €0.83

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.